Form 4: Vertex Pharmaceuticals EVP, COO Stuart A. Arbuckle Reports Stock Disposal
SEC Form 4 Filing
Stuart A. Arbuckle, EVP, COO of Vertex Pharmaceuticals, reports disposing of 2,724 shares of common stock to cover tax obligations.
Summary
- On February 14, 2025, Stuart A. Arbuckle, the EVP, COO of Vertex Pharmaceuticals, disposed of 2,724 shares of common stock.
- The transaction was executed at a price of $463.46 per share.
- This disposal was likely to cover tax obligations related to vesting of stock or option exercise.
- Following the transaction, Arbuckle directly owns 74,722 shares of Vertex Pharmaceuticals common stock and indirectly owns 140 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock disposal transaction |
| 02/19/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.